Arrangements and methods are provided for obtaining information associated with an anatomical sample. For example, at least one first electro-magnetic radiation can be provided to the anatomical sample so as to generate at least one acoustic wave in the anatomical sample. At least one second electro-magnetic radiation can be produced based on the acoustic wave. At least one portion of at least one second electro-magnetic radiation can be provided so as to determine information associated with at least one portion of the anatomical sample. In addition, the information based on data associated with the second electro-magnetic radiation can be analyzed. The first electro-magnetic radiation may include at least one first magnitude and at least one first frequency. The second electro-magnetic radiation can include at least one second magnitude and at least one second frequency. The data may relate to a first difference between the first and second magnitudes and/or a second difference between the first and second frequencies. The second difference may be approximately between −100 GHz and 100 GHz, excluding zero.

Methods of treating subjects having clonal hematopoiesis of indeterminate potential (CHIP) with lymphocyte antigen 75 (LY75), Cluster of Differentiation 164 (CD164), or Poly(ADP-Ribose) Polymerase 1 (PARP1) inhibitors, and methods of identifying subjects having an increased risk of developing CHIP are provided herein.

This disclosure provides systems and methods for mapping and/or measuring a mechanical property of a medium. The mechanical property can be measured by Brillouin spectroscopy. The systems and methods can include a three-dimensional imaging modality that is co-registered with a Brillouin probe beam of a Brillouin spectrometer. The three-dimensional imaging modality can be optical coherence tomography or Scheimpflug camera imaging.

DUX4 can be used as a biomarker for predicting a patient's response to immunotherapy, and inhibition of DUX4 can be used in therapeutic methods for treating DUX4+ cancers. Accordingly, aspects of the disclosure relate to a method for treating cancer in a patient comprising administering a DUX4 inhibitor to the patient. Further aspects of the disclosure relate to a method for treating a DUX4+ cancer in a patient, the method comprising administering a checkpoint inhibitor to the patient. Other aspects relate to a composition comprising a DUX4 inhibitor and a checkpoint inhibitor.

Arrangements and methods are provided for obtaining information associated with an anatomical sample. For example, at least one first electro-magnetic radiation can be provided to the anatomical sample so as to generate at least one acoustic wave in the anatomical sample. At least one second electro-magnetic radiation can be produced based on the acoustic wave. At least one portion of at least one second electro-magnetic radiation can be provided so as to determine information associated with at least one portion of the anatomical sample. In addition, the information based on data associated with the second electro-magnetic radiation can be analyzed. The first electro-magnetic radiation may include at least one first magnitude and at least one first frequency. The second electro-magnetic radiation can include at least one second magnitude and at least one second frequency. The data may relate to a first difference between the first and second magnitudes and/or a second difference between the first and second frequencies. The second difference may be approximately between −100 GHz and 100 GHz, excluding zero.

The invention provides improved strategies, prognostic indicators, compositions, and methods for producing personalized neoplasia vaccines. More particularly, embodiments of the present disclosure relate to the identification of neoplasia-specific neo-epitopes to predict survival and to identify and design subject-specific neo-epitopes, further assessing the identified neo-epitopes encoded by said mutations to identify neo-epitopes that are known or determined, or predicted to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells), and excluding such neo-epitopes that are known, determined, or predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) from the subject-specific neo-epitopes that are to be used in personalized neoplasia vaccines. The present disclosure further relates to a novel ranking system for determining the optimal subject-specific neo-epitopes that are to be used in personalized neoplasia vaccines.

Disclosed are the development of a recombinant chicken IgY monoclonal antibody and a recombinant chicken IgY single-chain variable fragment (scFv) antibody raised against human thymidine kinase 1 in mammalian cells and a preparation method and use thereof. A light chain of the scFv antibody includes an amino acid sequence shown in SEQ ID NO: 1, and a heavy chain of the scFv antibody includes an amino acid sequence shown in SEQ ID NO: 2.

This disclosure provides systems and methods for mapping and/or measuring a mechanical property of a medium. The mechanical property can be measured by Brillouin spectroscopy. The systems and methods can include a three-dimensional imaging modality that is co-registered with a Brillouin probe beam of a Brillouin spectrometer. The three-dimensional imaging modality can be optical coherence tomography or Scheimpflug camera imaging.

The present invention relates to an in vitro method for the prognosis of the survival time of a patient suffering from a solid cancer, comprising the quantification of the cell density of follicular B cells present in tumor-induced lymphoid structures from said patient, wherein a high density of follicular B cells indicates that the patient has a favorable prognosis and a low density of follicular B cells indicates that the patient has a poor prognosis.

Arrangements and methods are provided for obtaining informationassociated with an anatomical sample. For example, at least one first electro-magnetic radiation can be provided to the anatomical sample so as to generate at least one acoustic wave in the anatomical sample. At least one second electro-magnetic radiation can be produced based on the acoustic wave. At least one portion of at least one second electro-magnetic radiation can be provided so as to determine information associated with at least one portion of the anatomical sample. In addition, the information based on data associated with the second electro-magnetic radiation can be analyzed. The first electro-magnetic radiation may include at least one first magnitude and at least one first frequency. The second electro-magnetic radiation can include at least one second magnitude and at least one second frequency. The data may relate to a first difference between the first and second magnitudes and/or a second difference between the first and second frequencies. The second difference may be approximately between 100 GHz and 100 GHz, excluding zero.